MLchartDataset catalogue

Patent · US11259528B2 · B2 · US

System and methods for treatment of wounds with negative pressure and peroxy pyruvic acid

(11) Publication number
US11259528B2
(21) Application number
15/392,232
(22) Filing date
2016-12-28
(30) Priority date
2015-12-29
(43) Publication date
2022-03-01
(45) Date of grant
2022-03-01
(51) IPC
A21B 1/48; A21B 3/07; A21B 3/18; A21C 9/08; A47F 3/02; A61F 13/00; A61F 13/02; A61K 9/22; A61M 1/00; A61M 27/00; B65G 47/52; B65G 47/57; B65G 47/64
(52) CPC
  • A01N Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. as disinfectants, as pesticides or as herbicides; pest repellants or attractants; plant growth regulators: 37/16
  • A21B Bakers' ovens; machines or equipment for baking: 1/48, 3/07, 3/18
  • A21C Machines or equipment for making or processing doughs; handling baked articles made from dough: 9/083
  • A47F Special furniture, fittings, or accessories for shops, storehouses, bars, restaurants or the like; paying counters: 2003/021
  • A61M Devices for introducing media into, or onto, the body; devices for transducing body media or for taking media from the body; devices for producing or ending sleep or stupor {}: 1/77, 1/915, 1/92, 1/96
  • B65G Transport or storage devices, e.g. conveyors for loading or tipping, shop conveyor systems or pneumatic tube conveyors: 47/52, 47/57, 47/644
(73) Assignee
KCI Licensing Inc
(72) Inventors
Shannon C. Ingram; Christopher A. Carroll
(54) Title
System and methods for treatment of wounds with negative pressure and peroxy pyruvic acid
(57) Abstract

In one example embodiment, a system for treating a tissue site is disclosed comprising a dressing adapted to contact the tissue site and provide a fluid seal between a therapeutic environment and a local external environment, and a solution source fluidly coupled to the dressing and adapted to deliver an antimicrobial solution comprising a peroxy α-keto carboxylic acid, such as peroxy pyruvic acid, to the tissue interface. The system may further comprise a negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial fluid to the therapeutic environment. In another example embodiment, a method for treating a tissue site is disclosed comprising positioning a tissue interface to contact the tissue site, covering the tissue interface and the tissue site with a drape to provide a fluid seal between the therapeutic environment and the local external environment, and delivering an antimicrobial solution comprising peroxy α-keto carboxylic acid to the therapeutic environment before providing negative pressure to the therapeutic environment.

Full text
View on Google Patents

Claims (14)

  1. A system for treating a tissue site, comprising: a dressing including a manifold adapted to contact the tissue site and a cover adapted to provide a fluid seal between a therapeutic environment including the manifold proximate one side of the cover and a local external environment on the other side of the cover; a fluid-delivery interface fluidly coupled to the dressing, wherein the fluid-delivery interface comprises an inlet pad; a positive-pressure source operable to fluidly couple to a solution source and adapted to actuate a solution source for delivering an antimicrobial solution comprising peroxy pyruvic acid to the manifold; and a negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial solution to the manifold; wherein the manifold comprises a porous foam material having interconnected pores for distributing the antimicrobial solution to the therapeutic environment; and wherein the pores have a size of 400 to 600 microns; and wherein the antimicrobial solution comprises the peroxy pyruvic acid at a concentration of about 2% to about 0.005%.
  2. The system according to claim 1, wherein the negative-pressure source is further adapted to provide negative pressure to the therapeutic environment before or during delivery of the antimicrobial solution to the manifold.
  3. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source to provide a target pressure to the therapeutic environment in a pressure control mode.
  4. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source to provide a variable target pressure to the therapeutic environment in a dynamic pressure mode.
  5. The system according to claim 1, further comprising a processor operatively coupled to the positive-pressure source to provide the antimicrobial solution to the manifold for one or both of a predetermined dosage or a predetermined time.
  6. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source and the positive-pressure source to provide negative pressure to the therapeutic environment prior to, during, or after providing the antimicrobial solution to the manifold.
  7. The system according to claim 1, wherein the solution source is a container filled with the antimicrobial solution.
  8. A method for treating a tissue site, comprising: positioning a manifold to contact the tissue site; covering the manifold and the tissue site with a drape to provide a fluid seal between a therapeutic environment including the manifold on one side of the drape and a local external environment on the other side of the drape; fluidly coupling a fluid-delivery interface to the dressing, wherein the fluid-delivery interface comprises an inlet pad; delivering an antimicrobial solution comprising peroxy pyruvic acid from a solution source fluidly coupled to the manifold; and providing negative pressure to the therapeutic environment after delivery of the antimicrobial solution to the manifold from a negative-pressure source fluidly coupled to the therapeutic environment; wherein the manifold comprises a porous foam material having interconnected pores for distributing the antimicrobial solution to the therapeutic environment; and wherein the pores have a size of 400 to 600 microns; and wherein the antimicrobial solution comprises the peroxy pyruvic acid at a concentration of about 2% to about 0.005%.
  9. The method according to claim 8, further providing negative pressure to the therapeutic environment before or during delivery of the antimicrobial solution.
  10. The method according to claim 8, further providing the antimicrobial solution to the manifold in a predetermined dosage.
  11. The method according to claim 8, further providing the antimicrobial solution to the manifold for a predetermined time.
  12. The method according to claim 8, wherein the delivering of the antimicrobial solution comprises an intermittent flow of fluid soaking the manifold for about one second to about thirty minutes.
  13. The method according to claim 8, wherein the providing the negative pressure and the providing the antimicrobial solution are sequentially repeated two or more times.
  14. A dressing for treating a tissue site, comprising: a porous foam material having interconnected pores forming passageways for distributing negative pressure to the tissue site and adapted to contact the tissue site; a cover adapted to provide a fluid seal between a therapeutic environment including the porous foam material proximate one side of the cover and a local external environment on the other side of the cover; and an antimicrobial solution comprising a peroxy pyruvic acid at a concentration of about 2% to about 0.005% permeating at least a portion of the porous foam material; wherein the porous foam material has a pore size of 400 to 600 microns and operable to deliver both negative pressure and the antimicrobial solution to the therapeutic environment.

Description

The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to treating wounds with negative pressure and instillation of an antimicrobial solution in a negative-pressure and instillation therapy environment.

Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” “vacuum-assisted closure,” and “topical negative-pressure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.

There is also widespread acceptance that cleansing a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed out with a stream of liquid solution, or a cavity can be washed out using a liquid solution for therapeutic purposes.

Citations (159)

  • US1355846A
  • US2547758A
  • US2632443A
  • GB692578A
  • US2682873A
  • US2910763A
  • US2969057A
  • US3066672A
  • US3367332A
  • US3520300A
  • US3568675A
  • US3682180A
  • US3648692A
  • US3826254A
  • US4096853A
  • DE2640413A1
  • US4245630A
  • US4233969A
  • US4080970A
  • US4139004A
  • US4184510A
  • US4165748A
  • US4256109A
  • US4275721A
  • US4382441A
  • WO1980002182A1
  • US4284079A
  • US4261363A
  • US4569348A
  • US4480638A
  • US4297995A
  • US4333468A
  • US4465485A
  • US4392853A
  • US4373519A
  • US4392858A
  • US4419097A
  • AU550575B2
  • US4608041A
  • US4525166A
  • US4551139A
  • US4475909A
  • EP0100148A1
  • EP0117632A2
  • US4548202A
  • US4540412A
  • US4543100A
  • US4525374A
  • EP0161865A2
  • US4897081A
  • US5215522A
  • US4664662A
  • US4872450A
  • US4655754A
  • US4826494A
  • US4605399A
  • US5037397A
  • US4640688A
  • US4710165A
  • US4758220A
  • US4733659A
  • WO1987004626A1
  • US4838883A
  • US4906233A
  • US4840187A
  • GB2195255A
  • US4743232A
  • US4878901A
  • US4953565A
  • GB2197789A
  • US4941882A
  • US4787888A
  • US4863449A
  • US5176663A
  • US4906240A
  • US4985019A
  • EP0358302A2
  • GB2220357A
  • US4919654A
  • CA2005436A1
  • US5086170A
  • WO1990010424A1
  • US4969880A
  • US5100396A
  • US5527293A
  • US5261893A
  • US5298015A
  • US5358494A
  • US5232453A
  • GB2235877A
  • US5134994A
  • US5092858A
  • US5149331A
  • US5278100A
  • US5636643A
  • WO1993009727A1
  • US5645081A
  • US5279550A
  • US5167613A
  • US5437622A
  • DE4306478A1
  • WO1994020041A1
  • US6241747B1
  • US5342376A
  • US5344415A
  • US5437651A
  • US5549584A
  • US5556375A
  • US5607388A
  • US6493568B1
  • WO1996005873A1
  • DE29504378U1
  • WO1997018007A1
  • US6135116A
  • WO1999013793A1
  • US6814079B2
  • AU755496B2
  • GB2333965A
  • US6553998B2
  • US6345623B1
  • AU745271B2
  • GB2329127A
  • EP1018967A1
  • US6071267A
  • US6488643B1
  • US6287316B1
  • JP4129536B2
  • US20020120185A1
  • US20020077661A1
  • US20020115951A1
  • US20020143286A1
  • US7896864B2
  • US8062273B2
  • US9211365B2
  • US7846141B2
  • US8834451B2
  • US8398614B2
  • US8535296B2
  • US8926592B2
  • US8257327B2
  • US9289542B2
  • US8449509B2
  • US9198801B2
  • US8529548B2
  • US20150080788A1
  • US8034037B2
  • WO2007031765A1
  • US20100106079A1
  • US20140163491A1
  • US8551060B2
  • US9017302B2
  • US8679081B2
  • US8216198B2
  • US8251979B2
  • US8568386B2
  • US9044527B2
  • WO2012112951A1
  • US20130211348A1
  • US20150320434A1
Record as JSON 
{
  "publication_number": "US11259528B2",
  "country": "US",
  "kind": "B2",
  "title": "System and methods for treatment of wounds with negative pressure and peroxy pyruvic acid",
  "abstract": "In one example embodiment, a system for treating a tissue site is disclosed comprising a dressing adapted to contact the tissue site and provide a fluid seal between a therapeutic environment and a local external environment, and a solution source fluidly coupled to the dressing and adapted to deliver an antimicrobial solution comprising a peroxy α-keto carboxylic acid, such as peroxy pyruvic acid, to the tissue interface. The system may further comprise a negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial fluid to the therapeutic environment. In another example embodiment, a method for treating a tissue site is disclosed comprising positioning a tissue interface to contact the tissue site, covering the tissue interface and the tissue site with a drape to provide a fluid seal between the therapeutic environment and the local external environment, and delivering an antimicrobial solution comprising peroxy α-keto carboxylic acid to the therapeutic environment before providing negative pressure to the therapeutic environment.",
  "claims": [
    "1. A system for treating a tissue site, comprising: a dressing including a manifold adapted to contact the tissue site and a cover adapted to provide a fluid seal between a therapeutic environment including the manifold proximate one side of the cover and a local external environment on the other side of the cover; a fluid-delivery interface fluidly coupled to the dressing, wherein the fluid-delivery interface comprises an inlet pad; a positive-pressure source operable to fluidly couple to a solution source and adapted to actuate a solution source for delivering an antimicrobial solution comprising peroxy pyruvic acid to the manifold; and a negative-pressure source fluidly coupled to the dressing and adapted to provide negative pressure to the therapeutic environment after delivery of the antimicrobial solution to the manifold; wherein the manifold comprises a porous foam material having interconnected pores for distributing the antimicrobial solution to the therapeutic environment; and wherein the pores have a size of 400 to 600 microns; and wherein the antimicrobial solution comprises the peroxy pyruvic acid at a concentration of about 2% to about 0.005%.",
    "2. The system according to claim 1, wherein the negative-pressure source is further adapted to provide negative pressure to the therapeutic environment before or during delivery of the antimicrobial solution to the manifold.",
    "3. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source to provide a target pressure to the therapeutic environment in a pressure control mode.",
    "4. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source to provide a variable target pressure to the therapeutic environment in a dynamic pressure mode.",
    "5. The system according to claim 1, further comprising a processor operatively coupled to the positive-pressure source to provide the antimicrobial solution to the manifold for one or both of a predetermined dosage or a predetermined time.",
    "6. The system according to claim 1, further comprising a processor operatively coupled to the negative-pressure source and the positive-pressure source to provide negative pressure to the therapeutic environment prior to, during, or after providing the antimicrobial solution to the manifold.",
    "7. The system according to claim 1, wherein the solution source is a container filled with the antimicrobial solution.",
    "8. A method for treating a tissue site, comprising: positioning a manifold to contact the tissue site; covering the manifold and the tissue site with a drape to provide a fluid seal between a therapeutic environment including the manifold on one side of the drape and a local external environment on the other side of the drape; fluidly coupling a fluid-delivery interface to the dressing, wherein the fluid-delivery interface comprises an inlet pad; delivering an antimicrobial solution comprising peroxy pyruvic acid from a solution source fluidly coupled to the manifold; and providing negative pressure to the therapeutic environment after delivery of the antimicrobial solution to the manifold from a negative-pressure source fluidly coupled to the therapeutic environment; wherein the manifold comprises a porous foam material having interconnected pores for distributing the antimicrobial solution to the therapeutic environment; and wherein the pores have a size of 400 to 600 microns; and wherein the antimicrobial solution comprises the peroxy pyruvic acid at a concentration of about 2% to about 0.005%.",
    "9. The method according to claim 8, further providing negative pressure to the therapeutic environment before or during delivery of the antimicrobial solution.",
    "10. The method according to claim 8, further providing the antimicrobial solution to the manifold in a predetermined dosage.",
    "11. The method according to claim 8, further providing the antimicrobial solution to the manifold for a predetermined time.",
    "12. The method according to claim 8, wherein the delivering of the antimicrobial solution comprises an intermittent flow of fluid soaking the manifold for about one second to about thirty minutes.",
    "13. The method according to claim 8, wherein the providing the negative pressure and the providing the antimicrobial solution are sequentially repeated two or more times.",
    "14. A dressing for treating a tissue site, comprising: a porous foam material having interconnected pores forming passageways for distributing negative pressure to the tissue site and adapted to contact the tissue site; a cover adapted to provide a fluid seal between a therapeutic environment including the porous foam material proximate one side of the cover and a local external environment on the other side of the cover; and an antimicrobial solution comprising a peroxy pyruvic acid at a concentration of about 2% to about 0.005% permeating at least a portion of the porous foam material; wherein the porous foam material has a pore size of 400 to 600 microns and operable to deliver both negative pressure and the antimicrobial solution to the therapeutic environment."
  ],
  "description_excerpt": "The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to treating wounds with negative pressure and instillation of an antimicrobial solution in a negative-pressure and instillation therapy environment.\n\nClinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” “vacuum-assisted closure,” and “topical negative-pressure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.\n\nThere is also widespread acceptance that cleansing a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed out with a stream of liquid solution, or a cavity can be washed out using a liquid solution for therapeutic purposes.",
  "cpc": [
    "A01N 37/16",
    "A21B 1/48",
    "A21B 3/07",
    "A21B 3/18",
    "A21C 9/083",
    "A47F 2003/021",
    "A61M 1/77",
    "A61M 1/915",
    "A61M 1/92",
    "A61M 1/96",
    "B65G 47/52",
    "B65G 47/57",
    "B65G 47/644"
  ],
  "ipc": [
    "A21B 1/48",
    "A21B 3/07",
    "A21B 3/18",
    "A21C 9/08",
    "A47F 3/02",
    "A61F 13/00",
    "A61F 13/02",
    "A61K 9/22",
    "A61M 1/00",
    "A61M 27/00",
    "B65G 47/52",
    "B65G 47/57",
    "B65G 47/64"
  ],
  "assignees": [
    "KCI Licensing Inc"
  ],
  "inventors": [
    "Shannon C. Ingram",
    "Christopher A. Carroll"
  ],
  "filing_date": "2016-12-28",
  "publication_date": "2022-03-01",
  "grant_date": "2022-03-01",
  "priority_date": "2015-12-29",
  "application_number": "US-201615392232-A",
  "family_id": "57799925",
  "cited_by_count": 1,
  "citations": [
    "US1355846A",
    "US2547758A",
    "US2632443A",
    "GB692578A",
    "US2682873A",
    "US2910763A",
    "US2969057A",
    "US3066672A",
    "US3367332A",
    "US3520300A",
    "US3568675A",
    "US3682180A",
    "US3648692A",
    "US3826254A",
    "US4096853A",
    "DE2640413A1",
    "US4245630A",
    "US4233969A",
    "US4080970A",
    "US4139004A",
    "US4184510A",
    "US4165748A",
    "US4256109A",
    "US4275721A",
    "US4382441A",
    "WO1980002182A1",
    "US4284079A",
    "US4261363A",
    "US4569348A",
    "US4480638A",
    "US4297995A",
    "US4333468A",
    "US4465485A",
    "US4392853A",
    "US4373519A",
    "US4392858A",
    "US4419097A",
    "AU550575B2",
    "US4608041A",
    "US4525166A",
    "US4551139A",
    "US4475909A",
    "EP0100148A1",
    "EP0117632A2",
    "US4548202A",
    "US4540412A",
    "US4543100A",
    "US4525374A",
    "EP0161865A2",
    "US4897081A",
    "US5215522A",
    "US4664662A",
    "US4872450A",
    "US4655754A",
    "US4826494A",
    "US4605399A",
    "US5037397A",
    "US4640688A",
    "US4710165A",
    "US4758220A",
    "US4733659A",
    "WO1987004626A1",
    "US4838883A",
    "US4906233A",
    "US4840187A",
    "GB2195255A",
    "US4743232A",
    "US4878901A",
    "US4953565A",
    "GB2197789A",
    "US4941882A",
    "US4787888A",
    "US4863449A",
    "US5176663A",
    "US4906240A",
    "US4985019A",
    "EP0358302A2",
    "GB2220357A",
    "US4919654A",
    "CA2005436A1",
    "US5086170A",
    "WO1990010424A1",
    "US4969880A",
    "US5100396A",
    "US5527293A",
    "US5261893A",
    "US5298015A",
    "US5358494A",
    "US5232453A",
    "GB2235877A",
    "US5134994A",
    "US5092858A",
    "US5149331A",
    "US5278100A",
    "US5636643A",
    "WO1993009727A1",
    "US5645081A",
    "US5279550A",
    "US5167613A",
    "US5437622A",
    "DE4306478A1",
    "WO1994020041A1",
    "US6241747B1",
    "US5342376A",
    "US5344415A",
    "US5437651A",
    "US5549584A",
    "US5556375A",
    "US5607388A",
    "US6493568B1",
    "WO1996005873A1",
    "DE29504378U1",
    "WO1997018007A1",
    "US6135116A",
    "WO1999013793A1",
    "US6814079B2",
    "AU755496B2",
    "GB2333965A",
    "US6553998B2",
    "US6345623B1",
    "AU745271B2",
    "GB2329127A",
    "EP1018967A1",
    "US6071267A",
    "US6488643B1",
    "US6287316B1",
    "JP4129536B2",
    "US20020120185A1",
    "US20020077661A1",
    "US20020115951A1",
    "US20020143286A1",
    "US7896864B2",
    "US8062273B2",
    "US9211365B2",
    "US7846141B2",
    "US8834451B2",
    "US8398614B2",
    "US8535296B2",
    "US8926592B2",
    "US8257327B2",
    "US9289542B2",
    "US8449509B2",
    "US9198801B2",
    "US8529548B2",
    "US20150080788A1",
    "US8034037B2",
    "WO2007031765A1",
    "US20100106079A1",
    "US20140163491A1",
    "US8551060B2",
    "US9017302B2",
    "US8679081B2",
    "US8216198B2",
    "US8251979B2",
    "US8568386B2",
    "US9044527B2",
    "WO2012112951A1",
    "US20130211348A1",
    "US20150320434A1"
  ]
}

Record 1,262 of 8,000 in Patents full text (MLC-0201). Request the full dataset.